Heart Function and Exercise Capacity in Patients With Hypertrophic Cardiomyopathy
Information source: National Institutes of Health Clinical Center (CC)
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Angina, Unstable; Myocardial Infarction; Ischemic Heart Disease
Phase: N/A
Status: Active, not recruiting
Sponsored by: National Heart, Lung, and Blood Institute (NHLBI)
Summary
This study will examine the relationship between certain measures of heart function and
exercise capacity in patients with hypertrophic cardiomyopathy (HCM).
Patients who participated in NHLBI studies 01-H-0006 ("Double Blind Placebo-Controlled Study
of Pirfenidone - A Novel Anti-Fibrotic Drug - in Symptomatic Patients with Hypertrophic
Cardiomyopathy Associated with Left Ventricular Diastolic Dysfunction") and 96-H-0144
("Double Blind Placebo-Controlled Study of Long-Term Effects of Angiotensin-Converting Enzyme
Inhibition (Enalapril) and Angiotensin II Receptor Blockade (Losartan) on Genetically-Induced
Left Ventricular Diastolic Dysfunction") are eligible for this study. Data from
echocardiograms and measures of left ventricular pressure obtained from patients in those
studies will be analyzed in the current study to assess their influence on exercise capacity.
No additional tests, treatments or other procedures are required.
Information from this study may help in the development of improved drug treatments for HCM.
Clinical Details
Official title: Relationship of Diastolic Function and Functional Capacity in Hypertrophic Cardiomyopathy: a Post-Hoc Analysis of Protocols 01-H-0066 and 96-H-0144
Study design: N/A
Detailed description:
NIH Protocols 01-H-0066, Double Blind Placebo Controlled Study of Pirfenidone A Novel
Anti-Fibrotic Drug in Symptomatic patients with Hypertrophic Cardiomyopathy (HCM) Associated
with left Ventricular Diastolic Dysfunction and 96-H-0144, Double Blind Placebo-Controlled
Study of Long-Term Effects of Angiotensin Converting Enzyme Inhibition (Enalapril) and
Angiotensin II Receptor Blockade (Losartan) On Genetically-Induced Left Ventricular Diastolic
Dysfunction were undertaken to assess the effect of therapeutic interventions on left
ventricular (LV) diastolic function. The relationship between baseline measures of diastolic
function as assessed by noninvasive modalities such as Doppler echocardiography and
radionuclide angiography, and qualitative and objective measures of functional capacity in
patients without LV outflow tract obstruction has not been reported. In this protocol we
will look at measures of LV geometry, relaxation and novel indices of ventricular compliance
as they may influence measures of exercise capacity. In all cases, we will use pre-existing
baseline data obtained with informed consent as part of the above protocols.
Eligibility
Minimum age: 20 Years.
Maximum age: 75 Years.
Gender(s): Both.
Criteria:
- Eligibility criteria not listed; Analysis of data from previous studies.
Locations and Contacts
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland 20892, United States
Additional Information
NIH Clinical Center Detailed Web Page
Starting date: May 2005
Last updated: April 22, 2008
|
